S.22 (Act 61)

An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration

Sponsors: Sen. Virginia Lyons , Sen. Richard McCormack

Last Recorded Action: 5/21/2021 - Senate Message, signed by Governor <strong>June 7, 2021</strong>

Committee Activity - Meeting Full List

Regular Session 2021-2022

Wednesday, January 27, 2021
Committee(s):
Senate Committee on Health and Welfare
-

S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration

Introduction, walk through

Sen. Virginia "Ginny" Lyons, Sponsor, Chittenden County
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel

Wednesday, February 10, 2021
Committee(s):
Senate Committee on Health and Welfare
11:00 AM

S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration

Walk-through, committee discussion

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel

Friday, February 19, 2021
Committee(s):
Senate Committee on Health and Welfare
9:00 AM

S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration

Testimony

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont
Cindy Bruzzese, Executive Director & Clinical Ethicist, Vermont Ethics Network
David Herlihy, Executive Director, Vermont Board of Medical Practice
Jill Abrams, Assistant Attorney General, Director, Consumer Protection Division, Attorney General's Office
Jessa Barnard, Executive Director, Vermont Medical Society

Tuesday, February 23, 2021
Committee(s):
Senate Committee on Health and Welfare
10:10 AM

S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration

Committee discussion

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel

Friday, February 26, 2021
Committee(s):
Senate Committee on Health and Welfare
9:30 AM

S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration

Committee discussion, vote

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel

Friday, March 19, 2021
Committee(s):
House Committee on Health Care
1:30 PM

S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration

Walk-through

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel

Wednesday, April 7, 2021
Committee(s):
House Committee on Health Care
10:00 AM

S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration

Sen. Cheryl Hooker, Reporter, Senate Health and Welfare
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont
David Herlihy, Executive Director, Vermont Board of Medical Practice
Jessa Barnard, Executive Director, Vermont Medical Society
Cindy Bruzzese, Executive Director & Clinical Ethicist, Vermont Ethics Network
Jill Abrams, Assistant Attorney General, Director, Consumer Protection Division, Attorney General's Office

Wednesday, April 28, 2021
Committee(s):
House Committee on Health Care
9:00 AM

S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration

Committee discussion

Sam Russo, Vermont Association of Naturopathic Physicians
Lauren Hibbert, Director, Office of Professional Regulation, Secretary of State's Office

Friday, April 30, 2021
Committee(s):
House Committee on Health Care
10:50 AM

S.22 - An act relating to health care practitioners administering stem cell products not approved by the U.S. Food and Drug Administration

Vote